Projects / Programmes source: ARIS

Creation of tumor vaccines

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B520  Biomedical sciences  General pathology, pathological anatomy 
B200  Biomedical sciences  Cytology, oncology, cancerology 
experimental oncology, tumor immunology, tumor vaccines, gene therapy of cancer, cytokines, immunostimulators
Evaluation (rules)
source: COBISS
Researchers (15)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  18299  PhD Urška Čegovnik Primožič  Biochemistry and molecular biology  Researcher  2002 - 2004  37 
2.  03289  Jožica Červek  Oncology  Researcher  2002 - 2004  205 
3.  14441  MSc Darja Eržen  Oncology  Researcher  2002 - 2004  82 
4.  12023  PhD Marko Hočevar  Oncology  Researcher  2002 - 2004  470 
5.  12022  PhD Barbara Jezeršek Novaković  Oncology  Researcher  2002 - 2004  332 
6.  17175  PhD Igor Kocijančič  Neurobiology  Researcher  2002 - 2004  100 
7.  05278  PhD Jurij Lindtner  Oncology  Researcher  2002 - 2004  163 
8.  04377  Tadeja Movrin-Stanovnik  Oncology  Researcher  2002 - 2004  31 
9.  08007  PhD Srdjan Novaković  Oncology  Head  2002 - 2004  494 
10.  20053  PhD Maja Podkrajšek  Oncology  Researcher  2002 - 2004  52 
11.  12230  Franc Pompe  Oncology  Researcher  2002 - 2004  44 
12.  08750  PhD Zvonimir Rudolf  Oncology  Researcher  2002 - 2004  258 
13.  08800  PhD Gregor Serša  Oncology  Researcher  2002 - 2004  1,511 
14.  12250  PhD Marko Snoj  Oncology  Researcher  2002 - 2004  195 
15.  15836  MSc Bogdan Umek  Oncology  Researcher  2002 - 2004  11 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,447 
How to destroy cancer cells without damaging the normal cells? How to make conventional methods of systemic cancer treatment that predominantly comprise cytotoxic drugs more selective and prevent the development of drug resistance? There is an abundance of such questions that do not have simple answers. If, a few years ago, unselective cytotoxic drugs were the method of choice for the treatment of cancer, in the last 25 years we are witnessing the rapid transition of immunotherapy from the laboratories to the clinics. In this project, we present one of the applicable aspects of immunotherapy - i.e. the preparation of tumor vaccines. The proposition of the project is an extension of our former project in which we were pioneers in Slovenia in the development of tumor vaccines. In the context of the proposed project, we plan to prepare both syngeneic and allogeneic tumor vaccines. Both types of vaccines will be designed as classical tumor vaccines or by means of a genetic manipulation. Classical tumor vaccines will comprise sublethally irradiated tumor cells and nonspecific immunomodulators (the application of BCG and Detox is considered). Genetically modified vaccines will also include irradiated tumor cells into which the genes of interest will be introduced. The transfer of genes coding for TNF-α, IFN-γ, G-CSF, IL-2 or GM-CSF is planned in the form of plasmids to achieve the transient expression of these genes. Efforts will be made also to ligate two genes into one plasmid, and to introduce two plasmids comprising two different genes into the same cells. Basic tumor models applied in the follow-up of the effectiveness of the newly created vaccines will be the intraperitoneal and the subcutaneous B-16 tumor models. Our interest will be focused on the potency of the vaccines to prevent tumor development as well as on their effect against developed tumors. The proposed project represents a classical pre-clinical work where, with a series of in vitro and in vivo experiments, we intend to upgrade the preparation of various tumor vaccines, and to enlighten some basic mechanisms underlying the effects of tumor vaccines.
Views history